Patrick Soon-Shiong
Chinese-American billionaire physician, CEO & philanthropist
Patrick Soon-Shiong (Chinese: 黄馨祥; pinyin: Huáng Xīnxiáng; born July 29, 1952) is a South African and American businessman, researcher and surgeon who invented Abraxane, a drug used for lung, breast, and pancreatic cancer. He has been the owner and executive chairman of the Los Angeles Times since 2018.
Soon-Shiong received FDA approval for a new class of immunotherapy drug called Anktiva in non-muscle invasive bladder cancer in 2024. Soon-Shiong is the founder of NantWorks, a network of healthcare, biotech, and artificial intelligence startups; an adjunct professor of surgery and executive director of the Wireless Health Institute at the University of California, Los Angeles; and a visiting professor at Imperial College London and Dartmouth College. He is currently Executive Chairman, Global Chief Medical & Technology Officer at ImmunityBio.
Soon-Shiong is the chairman of Chan Soon-Shiong Family Foundation, a non-profit foundation. He has been a minority owner of the Los Angeles Lakers since 2010. Soon-Shiong's net worth is estimated at US$16.6 billion as of 2026 according to the Bloomberg Billionaires Index and Forbes. He has been called the richest man in Los Angeles and one of the wealthiest doctors in the world.
Early life and education
Soon-Shiong was born in Port Elizabeth (then part of the Union of South Africa) to Chinese immigrant parents who fled China during the Japanese occupation in World War II. His parents were Hakka Chinese originally from Meixian District in Guangdong province.
The public source identifies “Patrick Soon-Shiong” as chinese-American billionaire physician, CEO & philanthropist. This brief keeps that definition visible, then builds a research path around Patrick, Soon-Shiong and Chinese-American.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Patrick Soon-Shiong”, the useful work is to connect “chinese-American billionaire physician, CEO & philanthropist” to the records capable of establishing context and consequence.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Sep 6, 2026. The linked authority identifier is Q7147677. VIAF identifies the subject as 425149066346065600082. 2 of 2 selected statements include explicit references; 0 carry qualifiers and 0 use preferred rank. The first chronological checks are 1952, 2018, 2024 and 2010.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Patrick Soon-Shiong”, its source revision and the description used here.
- Expand the search: follow Patrick Soon-Shiong primary sources, Patrick Soon-Shiong archive and Patrick research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Patrick Soon-Shiong”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Patrick Soon-Shiong” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.